Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.

MLA

Ostrominski, John W., et al. “Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.” European Journal of Heart Failure, vol. 24, no. 10, Oct. 2022, pp. 1892–901. EBSCOhost, https://doi.org/10.1002/ejhf.2652.

APA

Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., de Boer, R. A., Desai, A. S., Dobreanu, D., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., Lam, C. S. P., Langkilde, A. M., Lindholm, D., Martinez, F. A., O’Meara, E., Petersson, M., Shah, S. J., Thierer, J., McMurray, J. J. V., & Solomon, S. D. (2022). Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure, 24(10), 1892–1901. https://doi.org/10.1002/ejhf.2652

Chicago

Ostrominski, John W, Muthiah Vaduganathan, Brian L Claggett, Rudolf A de Boer, Akshay S Desai, Dan Dobreanu, Adrian F Hernandez, et al. 2022. “Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.” European Journal of Heart Failure 24 (10): 1892–1901. doi:10.1002/ejhf.2652.